Behçet's Disease and the Burden of Chronicity: Interplay Between Physical Symptoms, Mental Health, and Quality of Life.

Behçet's disease (BD) is a rare, chronic, multisystem inflammatory disorder that profoundly affects patients' quality of life (QoL) through complex physical, psychological, and social burdens. Characterized by recurrent oral and genital ulcers, ocular involvement, vascular inflammation, and systemic manifestations, BD leads to fluctuating yet progressive impairment across multiple domains. Patients frequently experience significant declines in physical functioning, emotional well-being, and social participation, with higher rates of anxiety, depression, and cognitive disturbances than the general population. Studies report that over 50% of BD patients suffer from depression, and up to 60% experience anxiety disorders, with approximately 20% requiring psychotropic medications. Socioeconomic consequences, including unemployment, financial hardship, and social isolation, further exacerbate the disease burden. Health-related QoL assessments highlight substantial variability influenced by disease severity, age, sex, and cultural context. Generic QoL instruments, such as the Short Form-36 Health Survey (SF-36), offer valuable comparisons across diseases, but disease-specific tools like the Behçet's Disease Quality of Life (BDQoL) scale provide superior sensitivity to BD-specific impairments. Comprehensive management strategies that combine immunosuppressive therapy, psychological interventions, and social support are essential to address the full impact of BD. Routine monitoring of QoL alongside clinical markers can guide more personalized, patient-centered care and improve long-term outcomes. Early psychological screening and multidisciplinary interventions are particularly crucial in mitigating the bidirectional effects of physical and mental health deterioration. This review underscores the importance of adopting holistic, integrated approaches to BD management, prioritizing not only disease control but also the broader dimensions of patient well-being. Future research should focus on standardizing QoL measurements and developing longitudinal interventions tailored to the challenges of BD.